Last reviewed · How we verify
Placebo for quetiapine XR
Placebo for quetiapine XR is a Small molecule drug developed by University Hospitals Cleveland Medical Center. It is currently in Phase 3 development for Control arm in phase 3 trial for quetiapine XR efficacy evaluation. Also known as: Placebo for Seroquel XR.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in phase 3 trial for quetiapine XR efficacy evaluation.
At a glance
| Generic name | Placebo for quetiapine XR |
|---|---|
| Also known as | Placebo for Seroquel XR |
| Sponsor | University Hospitals Cleveland Medical Center |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the investigational drug.
Approved indications
- Control arm in phase 3 trial for quetiapine XR efficacy evaluation
Common side effects
Key clinical trials
- Quetiapine for Bipolar Disorder and Alcohol Dependence (PHASE4)
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
- Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder (PHASE2)
- Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression (PHASE4)
- Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency (PHASE2)
- Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) (PHASE3)
- Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD) (PHASE3)
- A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for quetiapine XR CI brief — competitive landscape report
- Placebo for quetiapine XR updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI
Frequently asked questions about Placebo for quetiapine XR
What is Placebo for quetiapine XR?
How does Placebo for quetiapine XR work?
What is Placebo for quetiapine XR used for?
Who makes Placebo for quetiapine XR?
Is Placebo for quetiapine XR also known as anything else?
What development phase is Placebo for quetiapine XR in?
Related
- Manufacturer: University Hospitals Cleveland Medical Center — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Control arm in phase 3 trial for quetiapine XR efficacy evaluation
- Also known as: Placebo for Seroquel XR
- Compare: Placebo for quetiapine XR vs similar drugs
- Pricing: Placebo for quetiapine XR cost, discount & access